Yoshiaki Amino

ORCID

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 11

Top Venues

Thoracic cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer (2024)
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer 15 (5) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer 15 (5) (2024)
Ayu Kiritani, Yoshiaki Amino, Ken Uchibori, Takahiro Akita, Yuhei Harutani, Shinsuke Ogusu, Ryosuke Tsugitomi, Ryo Manabe, Ryo Ariyasu, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Efficacy of osimertinib in patients with EGFR-mutation positive non-small cell lung cancer with malignant pleural effusion. Thoracic cancer 15 (5) (2024)
Takahiro Akita, Ryo Ariyasu, Sho Kakuto, Keiki Miyadera, Ayu Kiritani, Ryosuke Tsugitomi, Yoshiaki Amino, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Sadatomo Tasaka, Makoto Nishio
Distinction of ALK fusion gene- and EGFR mutation-positive lung cancer with tumor markers. Thoracic cancer 15 (10) (2024)
Yoshiaki Amino, Siew-Kee Low, Hironori Ninomiya, Ayu Kiritani, Keiki Miyadera, Sho Kakuto, Takahiro Akita, Ryosuke Tsugitomi, Ryo Ariyasu, Ken Uchibori, Satoru Kitazono, Noriko Yanagitani, Makoto Nishio
Clinical characteristics of patients with KRAS mutation detected by liquid biopsy. Thoracic cancer (2023)

Yoshiaki Amino.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yoshiaki Amino